## 4 Oct 2017, Wednesday-Scientific

### Oral Abstracts 3 - Hall 8a

<table>
<thead>
<tr>
<th>Time</th>
<th>Abstract</th>
<th>Presenter</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>ABLATION OF LONGSTANDING PERSISTENT ATRIAL FIBRILLATION USING THE ACQMAP 3-D MAPPING SYSTEM – AN EARLY SINGLE CENTRE EXPERIENCE</td>
<td>Ewen Shepherd</td>
<td>Newcastle upon Tyne UK</td>
</tr>
<tr>
<td>08:45</td>
<td>IMPROVING TARGET IDENTIFICATION OF PERSISTENT ATRIAL FIBRILLATION ABLATION USING SIMULTANEOUS INTRACARDIAC MAPPING</td>
<td>Xin Li</td>
<td>Leicester UK</td>
</tr>
<tr>
<td>09:00</td>
<td>ACCURACY OF LEFT ATRIAL BIPOLAR VOLTAGES OBTAINED BY CONFIDENCE MULTIELECTRODE MAPPING IN PATIENTS WITH PERSISTENT ATRIAL FIBRILLATION</td>
<td>Baptiste Maille</td>
<td>Liverpool UK</td>
</tr>
<tr>
<td>09:15</td>
<td>THE IMPACT OF THE PRESENCE OF LEFT ATRIAL LOW VOLTAGE AREAS ON OUTCOMES FROM PULMONARY VEIN ISOLATION</td>
<td>Fiyyaz Ahmed-Jushuf</td>
<td>London UK</td>
</tr>
<tr>
<td>09:30</td>
<td>POWER, LESION SIZE INDEX AND OESOPHAGEAL TEMPERATURE ALERTS DURING ATRIAL FIBRILLATION ABLATION (PILOT-AF): A RANDOMIZED STUDY</td>
<td>Milena Leo</td>
<td>Oxford UK</td>
</tr>
<tr>
<td>Time</td>
<td>Session Title</td>
<td>Speaker</td>
<td>Location</td>
</tr>
<tr>
<td>-------</td>
<td>-------------------------------------------------------------------------------</td>
<td>--------------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>09:45</td>
<td>Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>VT, EP &amp; AF Ablation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:45</td>
<td>EFFECT OF ACTIVATION WAVEFRONT ON ELECTROGRAM CHARACTERISTICS DURING VENTRICULAR TACHYCARDIA ABLATION</td>
<td>Claire Martin</td>
<td>Bordeaux FR</td>
</tr>
<tr>
<td>11:00</td>
<td>MULTIMODALITY IMAGE RECONSTRUCTION AND FUSION TO GUIDE VT ABLATION</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:15</td>
<td>APPLICATION OF THE NOVEL ‘SHANGHAI’ DIAGNOSTIC CRITERIA FOR BRUGADA SYNDROME REDUCES THE NUMBER OF DIAGNOSES WITH LOW RISK OF ARRHYTHMIC EVENTS IN INDEX CASES</td>
<td>Greg Mellor</td>
<td>Cambridge UK</td>
</tr>
<tr>
<td>11:30</td>
<td>DEVELOPMENT OF ATRIAL Fibrillation FOLLOWING ABLATION FOR TYPICAL ATRIAL FLUTTER CANNOT BE PREDICTED BY CONVENTIONAL RISK FACTORS; TIME FOR A RETHINK IN ABLATION STRATEGY?</td>
<td>M Mann</td>
<td>Liverpool UK</td>
</tr>
<tr>
<td>11:45</td>
<td>EVOLUTION OF PROMS DATA AND WHAT IT TELLS US ABOUT PATIENTS UNDERGOING CATHETER ABLATION FOR ATRIAL FIBRILLATION</td>
<td>J Girach</td>
<td>Leicester UK</td>
</tr>
<tr>
<td>12:00</td>
<td>ATRIAL FIBRILLATION ABLATION AS A DAY-CASE PROCEDURE: THREE-YEAR SINGLE-CENTRE EXPERIENCE</td>
<td>Stefano Bartoletti</td>
<td>Liverpool UK</td>
</tr>
<tr>
<td>12:15</td>
<td>Close</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## Future perspectives of patient optimization in heart failure - Sponsored by Boston Scientific - Hall 8b

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>How can we treat more CRT-indicated patients with better outcome? The clinical and economic impact of longevity</td>
<td>Jay Wright</td>
<td>Liverpool UK</td>
</tr>
<tr>
<td>08:50</td>
<td>The Multisense trial: finally a new perspective for monitoring patients with heart failure</td>
<td>Roy Gardner</td>
<td>Glasgow UK</td>
</tr>
<tr>
<td>09:10</td>
<td>A multiparametric approach to efficiently manage patients with Heart Failure: the HeartLogic philosophy</td>
<td>Martin Cowie</td>
<td>London UK</td>
</tr>
<tr>
<td>09:30</td>
<td>Can we save time and maximize outcome with Smart CRT Programming at implantation and follow-up?</td>
<td>Alison Seed</td>
<td>Blackpool UK</td>
</tr>
<tr>
<td>09:50</td>
<td>Discussion</td>
<td>Martin Cowie</td>
<td>London UK</td>
</tr>
<tr>
<td>10:00</td>
<td>Close</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session Title</td>
<td>Speaker</td>
<td>Location</td>
</tr>
<tr>
<td>-------</td>
<td>--------------------------------------------------------------------------------------------------------</td>
<td>------------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>08:30</td>
<td>Is there such a thing as having too much choice? Which NOAC to choose for which patient?</td>
<td>Irina Savelieva</td>
<td>London UK</td>
</tr>
<tr>
<td>09:00</td>
<td>What constitutes a total contraindication to oral anticoagulation in the NOAC era? Who to refer on for Left Atrial Appendage Occlusion?</td>
<td>Tim Betts</td>
<td>Oxford UK</td>
</tr>
<tr>
<td>09:30</td>
<td>Heart Failure in AF: how important is rate control with Beta Blockers?</td>
<td>Dipak Kotecha</td>
<td>Birmingham UK</td>
</tr>
<tr>
<td>10:00</td>
<td>Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:45</td>
<td>Mobile Apps and Devices: How have these impacted on AF detection and management?</td>
<td>Andre Ng</td>
<td>Leicester UK</td>
</tr>
<tr>
<td>11:15</td>
<td>Role of Biomarkers in stratifying stroke risk in AF; should the ABC score trump CHADSVASc score?</td>
<td>Dipak Kotecha</td>
<td>Birmingham UK</td>
</tr>
<tr>
<td>11:45</td>
<td>The relationship between AF burden and stroke risk: not what it seems?</td>
<td>Derick Todd</td>
<td>Liverpool UK</td>
</tr>
</tbody>
</table>
## Arrhythmia Alliance Improving care in patients at risk of sudden cardiac death - Hall 11

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>Sudden death post MI: epidemiology and risk</td>
<td>Andre Ng</td>
<td>Leicester UK</td>
</tr>
<tr>
<td>09:00</td>
<td>The role of the nurse specialist in SCD treatment/prevention</td>
<td>Craig Russell</td>
<td>Leeds UK</td>
</tr>
<tr>
<td>09:30</td>
<td>Management of recurrent VT: drugs and ablation</td>
<td>Prapa Kanagaratnam</td>
<td>London UK</td>
</tr>
<tr>
<td>10:00</td>
<td>Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:45</td>
<td>ARVC: what's new in arrhythmia management</td>
<td>Stephen Page</td>
<td>Leeds UK</td>
</tr>
<tr>
<td>11:15</td>
<td>Cardiac sarcoidosis: managing risk of sudden cardiac death</td>
<td>Kim Rajappan</td>
<td>Oxford UK</td>
</tr>
<tr>
<td>11:45</td>
<td>The role of gene-based pharmacotherapy in preventing SCD - science fiction or reality?</td>
<td>Pier Lambiase</td>
<td>London UK</td>
</tr>
<tr>
<td>12:15</td>
<td>Close</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
# The Zero Jargon Science Primer for Clinicians - Hall 8b

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Presenter</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:45</td>
<td>Reintroducing the Cardiac Action Potential - Everything You Need to Know But Were Too Afraid To Ask</td>
<td>Neil Herring</td>
<td>Oxford UK</td>
</tr>
<tr>
<td>11:00</td>
<td>How Fat Gives You AF - and what YOU can do about it</td>
<td>Fu Siong Ng</td>
<td>London UK</td>
</tr>
<tr>
<td>11:30</td>
<td>Stresses and Strains: the brain, the heart and autonomic feedback</td>
<td>Richard Ang</td>
<td>London UK</td>
</tr>
<tr>
<td>11:45</td>
<td>Traffic Jams and arrhythmias: causes and cures from ion channel trafficking</td>
<td>Stephen Harmer</td>
<td>London UK</td>
</tr>
<tr>
<td>12:15</td>
<td>Close</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>